Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom

2005 ◽  
Vol 156 (12) ◽  
pp. 367-371 ◽  
Author(s):  
C. Edlund Toulemonde ◽  
J. Daly ◽  
T. Sindle ◽  
P. M. Guigal ◽  
J. C. Audonnet ◽  
...  
Keyword(s):  
Influenza Virus ◽  
United Kingdom ◽  
Influenza Vaccine ◽  
Equine Influenza ◽  
The United Kingdom

scholarly journals Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results

2016 ◽  
Vol 21 (38) ◽  
Author(s):  
Richard Pebody ◽  
Fiona Warburton ◽  
Joanna Ellis ◽  
Nick Andrews ◽  
Alison Potts ◽  
...  
Keyword(s):  
Primary Care ◽  
United Kingdom ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Immunisation Programme ◽  
Influenza B ◽  
Live Attenuated Influenza Vaccine ◽  
The United Kingdom ◽  
Influenza A H1n1 ◽  
The Uk

The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season’s adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0–61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6–64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6) against influenza B. In 2–17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6–94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.

scholarly journals Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom

2014 ◽  
Vol 88 (22) ◽  
pp. 13269-13283 ◽  
Author(s):  
R. A. Elderfield ◽  
S. J. Watson ◽  
A. Godlee ◽  
W. E. Adamson ◽  
C. I. Thompson ◽  
...  
Keyword(s):  
Influenza Virus ◽  
United Kingdom ◽  
The United Kingdom

The outbreak of equine influenza (H3N8) in the United Kingdom in 1989: diagnostic use of an antigen capture ELISA

1993 ◽  
Vol 133 (21) ◽  
pp. 515-519 ◽  
Author(s):  
G. Livesay ◽  
T. O'Neill ◽  
D. Hannant ◽  
M. Yadav ◽  
J. Mumford
Keyword(s):  
United Kingdom ◽  
Equine Influenza ◽  
Capture Elisa ◽  
Diagnostic Use ◽  
Antigen Capture Elisa ◽  
The United Kingdom ◽  
Antigen Capture

Equine influenza in the United Kingdom in 1998

1999 ◽  
Vol 145 (16) ◽  
pp. 449-452 ◽  
Author(s):  
J. R. Newton ◽  
K. Verheyen ◽  
J. L. N. Wood ◽  
P. J. Yates ◽  
J. A. Mumford
Keyword(s):  
United Kingdom ◽  
Equine Influenza ◽  
The United Kingdom

scholarly journals Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17

2018 ◽  
Vol 23 (39) ◽  
Author(s):  
Richard G Pebody ◽  
Fiona Warburton ◽  
Nick Andrews ◽  
Mary Sinnathamby ◽  
Ivelina Yonova ◽  
...  
Keyword(s):  
United Kingdom ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Vaccine Uptake ◽  
Attributable Mortality ◽  
Influenza B ◽  
Age Group ◽  
The United Kingdom ◽  
Negative Case ◽  
Influenza A H1n1

Background In 2016/17, seasonal influenza vaccine was less effective in those aged 65 years and older in the United Kingdom. We describe the uptake, influenza-associated mortality and adjusted vaccine effectiveness (aVE) in this age group over influenza seasons 2010/11–2016/17. Methods: Vaccine uptake in 2016/17 and five previous seasons were measured using a sentinel general practitioners cohort in England; the test-negative case-control design was used to estimate pooled aVE by subtype and age group against laboratory-confirmed influenza in primary care from 2010–2017. Results: Vaccine uptake was 64% in 65–69-year-olds, 74% in 70–74-year-olds and 80% in those aged 75 and older. Overall aVE was 32.5% (95% CI: 11.6 to 48.5); aVE by sub-type was 60.8% (95% CI: 33.9 to 76.7) and 50.0% (95% CI: 21.6 to 68.1) against influenza A(H1N1)pdm09 and influenza B, respectively, but only 5.6% (95% CI: - 39.2 to 35.9) against A(H3N2). Against all laboratory-confirmed influenza aVE was 45.2% (95% CI: 25.1 to 60.0) in 65–74 year olds; - 26.2% (95% CI: - 149.3 to 36.0) in 75–84 year olds and - 3.2% (95% CI: - 237.8 to 68.5) in those aged 85 years and older. Influenza-attributable mortality was highest in seasons dominated by A(H3N2). Conclusions: Vaccine uptake with non-adjuvanted, normal-dose vaccines remained high, with evidence of effectiveness against influenza A(H1N1)pdm09 and B, though poor against A(H3N2), particularly in those aged 75 years and older. Forthcoming availability of newly licensed vaccines with wider use of antivirals can potentially further improve prevention and control of influenza in this group.

Sign in / Sign up

Export Citation Format

Share Document